Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Macro

Medicare Shakeup: Policy Changes Rattle Big Insurers

by Team Lumida
May 17, 2024
in Macro, News
Reading Time: 4 mins read
A A
0
emergency signage

Photo by Pixabay on Pexels.com

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  1. Biden administration’s policy changes reduce Medicare Advantage profitability.
  2. Insurers like CVS and Humana face rising costs and declining profits.
  3. Market and regulatory challenges could reshape the future of Medicare Advantage.

What Happened?

The Medicare Advantage landscape has dramatically shifted. Medicare Advantage, a program where the government pays insurers to manage senior care, has been a major profit driver for companies like UnitedHealth Group and Humana. However, the Biden administration’s recent policy changes have altered the payment structures, causing a significant dip in profitability.

CVS Health’s Aetna unit reported a $900 million surge in unexpected medical costs, leading to its largest one-day share drop in nearly 15 years. As a result, CVS shares have plunged 26% this year, equating to a market cap of just over $70 billion—the same amount it paid for Aetna in 2018. Humana and UnitedHealth have also seen their shares drop by over 20% and 16%, respectively.

Why It Matters?

These changes have rattled investors and corporate boards, signaling a shift from growth to profitability in the Medicare Advantage sector. With the government tightening its purse strings and implementing stricter policies, insurers must adapt quickly. CVS plans to exit some markets and cut back on benefits to improve margins.

Thomas Cowhey, CVS Chief Financial Officer, stated, “The goal for next year is margin over membership.” This shift could open opportunities for companies with better profit margins like UnitedHealth to gain market share. However, the regulatory environment remains a tougher challenge, with tighter payment rates and changes in coding patient risk.

What’s Next?

Insurers are now focusing on mitigating rising costs and adapting to new regulations. Expect strategic exits from less profitable markets and reductions in member benefits. Analysts predict Humana, despite expected lower earnings this year, will rebound to $26 per share by 2026. The industry’s lobbying efforts will intensify to influence public and policymaker opinions.

Wendell Potter, a former Cigna executive, highlighted, “Companies will be investing heavily through campaign donations and lobbying.” A potential Donald Trump win in the upcoming presidential elections could favor privatization and benefit Medicare Advantage. Regardless, the sector remains profitable but without the extraordinary gains seen in recent years.

Source: WSJ
Previous Post

Why Bitcoin’s Correlation with Nasdaq Is Skyrocketing

Next Post

Pharmacy Facelift: How Walgreens and CVS Aim to Boost Profits

Recommended For You

Wall Street Majors Cut Oil Forecasts on Deal to Reopen Hormuz

by Team Lumida
20 hours ago
Iran’s Island Fortress: The Five Strategic Positions Holding Hormuz Hostage

Goldman Sachs and Morgan Stanley slashed their oil price forecasts after the US-Iran interim deal, with Goldman expecting Brent at $80/barrel in Q4 and Persian Gulf exports back...

Read more

Blood Tests Can Now Detect Alzheimer’s. Should You Get One?

by Team Lumida
20 hours ago
person in white long sleeve shirt sitting on chair

Two FDA-cleared blood tests can now detect Alzheimer's markers, but neurologists caution they aren't designed for healthy people — and without approved preventive treatments, positive results create anxiety...

Read more

GM in Talks to Supply Weapons Parts to Lockheed Martin

by Team Lumida
20 hours ago
gray airplane

General Motors is in discussions with Lockheed Martin to manufacture components for the defense contractor's weapons systems, as the Trump administration presses automakers to help replenish US munitions...

Read more

Chinese Economy Stalls as Spending, Investment Drop to Covid-Era Levels

by Team Lumida
20 hours ago
China’s Bold Economic Moves: What You Need to Know Now

China's retail sales fell 0.6% year-on-year in May — the first decline since Covid lockdowns ended — while fixed-asset investment shrank 4.1%, exposing a deepening split between booming...

Read more

Polymarket Traders Clash Over $345 Million Iran Peace Market

by Team Lumida
20 hours ago
Indonesia Bans Polymarket After Bets on President Prabowo’s Removal Go Viral

Polymarket's $345 million Iran peace contract is in dispute: traders disagree on whether the US-Iran interim deal meets the contract's requirement for an explicit, permanent end to hostilities...

Read more

US and Iran Prepare for Deal Signing With Both Claiming Victory

by Team Lumida
20 hours ago
Israel Strikes the Caspian: Hitting the Russia–Iran Weapons Smuggling Pipeline at Its Source

The US and Iran are set to formally sign a 14-point interim peace MOU in Geneva on Friday, with JD Vance leading the American delegation — but disputes...

Read more

SpaceX Stock Set for More Than 50% Jump in Just Three Sessions

by Team Lumida
20 hours ago
SpaceX’s IPO Is So Big It’s Forcing Wall Street to Rewrite Its Own Rules

SpaceX shares surged another 11% in premarket Tuesday, putting the stock on track for a 50%+ gain across its first three trading sessions — lifting its market cap...

Read more

Kevin Warsh Wants the Fed to Stop Explaining Everything

by Team Lumida
2 days ago
September Rate Cut Likely as Job Market Risks Increase, Says Fed

New Federal Reserve Chairman Kevin Warsh is preparing to dramatically scale back Fed communications — fewer speeches, a possible end to the dot plot, and shorter press conferences...

Read more

Israel Is Alarmed by Trump’s Deal With Iran

by Team Lumida
2 days ago
Why Iran Thinks It Won the War — Despite Catastrophic Military Losses

Netanyahu is urgently seeking a meeting with Trump after an Israeli strike on Beirut nearly derailed the US-Iran agreement, and Israel worries Iran will pocket financial relief without...

Read more

SpaceX and OpenAI Are Ending Wall Street’s Era of Stock Scarcity

by Team Lumida
2 days ago
SpaceX’s IPO Is So Big It’s Forcing Wall Street to Rewrite Its Own Rules

A wave of mega-IPOs from SpaceX, OpenAI, and Anthropic — plus a record Alphabet share sale — is projected to flood markets with $1.5 trillion in new equity...

Read more
Next Post
woman with face mask holding an alcohol bottle

Pharmacy Facelift: How Walgreens and CVS Aim to Boost Profits

Revolutionizing AI: How DePIN is Solving Robots’ Biggest Blind Spot

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

New Oxford Study Links Ozempic to Dementia Prevention

New Oxford Study Links Ozempic to Dementia Prevention

July 12, 2024
Tech Titans Pivot: Silicon Valley’s New Alliance in Trump’s Second Term

Trump Threatens Far‑Reaching Cuts at Federal Agencies

October 3, 2025
brown wooden shelf with books

Global Supply Chains Brace for Trump’s Return: Companies Rush to Restructure Ahead of Potential Tariffs

December 27, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018